Rienzi

ZOA Energy Launches Revolutionary Supplement, ZOA+ Powder

Retrieved on: 
Monday, September 18, 2023
Electrolyte, Taste, USADA, Rienzi, Powder, NSF, Dwayne Johnson, Nitric oxide, Certification, Athlete, Trust, Rock, Walmart, Energy drink, Sport, Entrepreneurship, Safety, Boilermaker, Dietary supplement, ZOA, Costco, Amazon, Publix

TAMPA, Fla., Sept. 18, 2023 /PRNewswire/ -- ZOA Energy, the better-for-you energy drink, is introducing an unrivaled product to its impressive lineup. ZOA+ Powder – the 5-in-1 advanced formula pre-workout supplement designed to deliver maximum performance and mental focus – will set an uncompromising benchmark for innovative fitness standards. The all-new powder is now available exclusively at ZOAEnergy.com and Amazon.

Key Points: 
  • ZOA Energy Launches Revolutionary Supplement, ZOA+ Powder
    Formulated by ZOA Energy Co-founder and Chief Innovation Officer, Dave Rienzi, ZOA+ Powder promises a superior fitness experience.
  • This thoughtfully designed formula single-handedly addresses several pre-workout powder benefits, including maximum physical performance, sustained energy levels and focus, and hydration support, making ZOA+ Powder an essential companion in any workout regimen.
  • "ZOA+ Powder signifies our momentum and commitment to elevating the ZOA experience for our valued consumers.
  • ZOA Energy drinks are available nationwide at major U.S. retailers, such as Costco, Walmart, Publix, and more.

'What is the Clinical Value of Day 7 Blastocysts?' New Study Makes Case for Culturing Embryos Up to Seven Days Post-Insemination for Selected Patients

Retrieved on: 
Tuesday, May 3, 2022
Child, Genetic testing, LBS, Culture, Twitter, Failure, IVF, Health, Pregnancy, Research, Data collection, Patient, Infertility, TEL, Live birth, Angelo Cimadomo, Artificial intelligence, International Institute of Rehabilitation Sciences and Research, Observational study, LinkedIn, Rienzi, CEO, Technology, Portrait, Generalife, Entrepreneurship, Bias, Human Reproduction (journal), Medical device, Mineral oil, Silviculture, Science

TEL AVIV, Israel, May 3, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the results of a new study published in Human Reproduction, "How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144 hours (six days) post-insemination (h.p.i.) would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.

Key Points: 
  • A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence," finding that ending embryo culture at 144hours (six days) post-insemination (h.p.i.)
  • would involve 7.3 percent and 4.4 percent relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively.
  • "Fairtility's AI-powered tool can help IVF professionals make the most of time-lapse data through standardized and reproducible evaluations.
  • Here it made objective the clinical value of Day 7 embryos, opening up possibilities for couples struggling to get pregnant and to clinics contemplating a 6-to-7-day culture."